

Gastroenterology

Volume 165 / Issue 2

August 2023

www.gastrojournal.org

TABLE OF
CONTENTS

Contents

ON THE COVER



Fibroblasts Promote Dysplastic Progression in Metaplasia. See article by Lee, et al, page 374 for additional information.

COMMENTARIES

307 Becoming the Patient

J. Huang

309 Artificial Intelligence in Pancreatic Ductal Adenocarcinoma Imaging: A Commentary on Potential Future Applications

M. Schuurmans, N. Alves, P. Vendittelli, H. Huisman, J. Hermans, and PANCAIM Consortium

317 Translating the Microbiome: What's the Target?

P. W. O'Toole, T. S. Ghosh, S. Goswami, P. Manghi, N. Segata, and F. Shanahan

320 One ALT Is Not Like the Other

C. M. Hunt, T. H. Lee, T. R. Morgan, and S. Campbell

DIVERSITY, EQUITY, AND INCLUSION IN GI

324 Breaking Barriers in Dietary Research: Strategies to Diversify Recruitment in Clinical Studies and Develop Culturally Tailored Diets for Hispanic Communities Living With Inflammatory Bowel Disease

O. M. Damas and A. Maldonado-Contreras

MENTORING, EDUCATION, AND TRAINING CORNER

329 How to Become a Leader as a Fellow

I. Bhavsar-Burke and C. K. Dilly

Video Related article in CGH Hot Papers From New Investigators

CME quiz Editorial accompanies this article Additional online content available Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA. 2023 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

EDITORIALS

- 333 Risk Classification After Colonoscopy and Polypectomy: Are We Always Fighting the Last War?**

J. E. East

See Jodal HC et al on page 483.

- 336 Beyond Clinical Accuracy: Considerations for the Use of Generative Artificial Intelligence Models in Gastrointestinal Care**

K. Feldman and F. Nehme

See Lee T-S et al on page 509.

GASTRO CURBSIDE CONSULT

- 339 An Unusual Case of Diarrhea, Dysgeusia, and Grainy and Nodular Mucosa**

B.-Y. Zheng, X.-Y. Li, and L.-J. Zhang

- 347 A Woman With Recurrent Upper Gastrointestinal Bleeding**

S. L'Hermite, M. Bordet, and C. Rayer

- 350 An Unusual Faint Halo Around Colonic Ulcers**

W. Liu, M.-D. Zhou, and Q.-Y. Tong

- 354 Unexpected Abdominal Wall Varices After Split-Liver Transplantation**

  *C. Shen, J. Zhang, and Q. Xia*

ELECTRONIC GASTRO CURBSIDE CONSULT

For a full list, please see the table of contents online at www.gastrojournal.org.

ORIGINAL RESEARCH**Full Reports****Esophagus**

- 357 Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma**



S. Kumar, J. Zhao, S. Talluri, L. Buon, S. Mu, L. B. Potluri, C. Liao, J. Shi, C. Chakraborty, G. B. Gonzalez, Y.-T. Tai, J. Patel, J. Pal, H. Mashimo, M. K. Samur, N. C. Munshi, and M. A. Shammam

Inhibitors of a gene APE1 can potentially treat cancer without harming genetic material (DNA). They can also increase the efficacy of chemotherapy while reducing its toxicity to DNA.

Stomach

- 374 Apposition of Fibroblasts With Metaplastic Gastric Cells Promotes Dysplastic Transition**

 

S.-H. Lee, E. W. Contreras Panta, D. Gibbs, Y. Won, J. Min, C. Zhang, J. T. Roland, S.-H. Hong, Y. Sohn, E. Krystofiak, B. Jang, L. Ferri, V. Sangwan, J. Ragoussis, S. Camilleri-Broët, J. Caruso, C. Chen-Tanyolac, M. Strasser, P. Gascard, T. D. Tlsty, S. Huang, E. Choi, and J. R. Goldenring

Altered stromal fibroblasts in the precancerous gastric lining promote the transition of precancerous metaplastic cells into dysplasia, supporting the development of gastric cancer.

Helicobacter pylori

391 Effect of *Helicobacter pylori* Eradication Therapy on the Incidence of Noncardia Gastric Adenocarcinoma in a Large Diverse Population in the United States

D. Li, S.-F. Jiang, N. Y. Lei, S. C. Shah, and D. A. Corley

Helicobacter pylori eradication therapy was associated with a significant reduction in the risk of developing noncardia gastric adenocarcinoma based on results from a large, diverse, community-based population. These findings support the potential for substantial gastric cancer prevention through testing and eradication of *Helicobacter pylori* in the United States.

GI Cancer

402 A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients

X. Guo, Y. Peng, Q. Song, J. Wei, X. Wang, Y. Ru, S. Xu, X. Cheng, X. Li, D. Wu, L. Chen, B. Wei, X. Lv, and G. Ji

Our blood-based extracellular vesicle-derived lncRNA signature can enable clinicians to detect early-stage gastric cancer while it is still eligible for surgical resection, which can be of particular value in patients who may otherwise miss the window for radical surgery. This biomarker may aid in more reliable ability for early diagnosis and population screening of patients with gastric cancer.

414 Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis

L. Guo, Y. Wang, W. Yang, C. Wang, T. Guo, J. Yang, Z. Shao, G. Cai, S. Cai, L. Zhang, X. Hu, and Y. Xu

The genomic profiles of large-scale prospective sequencing in a Chinese colorectal cancer cohort highlighted the clinical insights of genomic information in predicting prognosis and improving targeted and immunologic treatment modalities.

429 Lymphatic Invasion of Plakoglobin-Dependent Tumor Cell Clusters Drives Formation of Polyclonal Lung Metastases in Colon Cancer

E. Küçükköse, J. Laoukili, A. N. Gorelick, S. Degner, M. M. Laclé, L. van den Bent, N. A. Peters, A. Verheem, W.-T. Hung, N. C. Frenkel, E. C. E. Wassenaar, N. Lansu, K. J. Lenos, L. Vermeulen, M. Koopman, J. M. L. Roodhart, G. J. P. L. Kops, I. H. M. Borel Rinkes, J. Hagendoorn, K. Naxerova, and O. Kranenburg

Analysis of colon cancer metastasis in mouse models and human tissues shows that lung metastases arise independently of liver metastases from tumor cell clusters gaining access to the lymphatic vasculature.

Colon

445 ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy

J. Zhai, H. Chen, C. C. Wong, Y. Peng, H. Gou, J. Zhang, Y. Pan, D. Chen, Y. Lin, S. Wang, W. Kang, K. F. To, Z. Chen, Y. Nie, H. H. He, J. J.-Y. Sung, and J. Yu

ALKBH5 promotes colorectal tumorigenesis by promoting immune suppression via an m⁶A-AXIN2-DKK1 axis. ALKBH5 is a potential therapeutic target for patients with colorectal cancer.

Hepatobiliary

463 Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study

D. Q. Huang, L. A. Wilson, C. Behling, D. E. Kleiner, K. V. Kowdley, S. Dasarathy, M. Amangurbanova, N. A. Terrault, A. M. Diehl, N. Chalasani, B. A. Neuschwander-Tetri, A. J. Sanyal, J. Tonascia, NASH Clinical Research Network, and R. Loomba

Liver fibrosis progresses faster in people with diabetes compared with people without diabetes.

Endoscopy

473 EUS-Guided Choledocho-duodenostomy Using Lumen Apposing Stent Versus ERCP With Covered Metallic Stents in Patients With Unresectable Malignant Distal Biliary Obstruction: A Multicenter Randomized Controlled Trial (DRA-MBO Trial)

A. Y. B. Teoh, B. Napoleon, R. Kunda, P. G. Arcidiacono, P. Kongkam, A. Larghi, S. Van der Merwe, J. Jacques, R. Legros, R.-E. Thawee, P. Saxena, M. Aerts, L. Archibugi, S. M. Chan, F. Fumex, A. J. Kaffes, M. T. W. Ma, N. Messaoudi, G. Rizzatti, K. K. C. Ng, E. K. W. Ng, and P. W. Y. Chiu

Endosonography-guided choledocho-duodenostomy and endoscopic retrograde cholangiopancreatography could be options for primary biliary drainage in unresectable malignant biliary obstructions. Primary choledocho-duodenostomy may be preferred when difficult endoscopic retrograde cholangiopancreatoscopies are anticipated.

Prevention and Early Detection

483 A Comparison of Risk Classification Systems of Colorectal Adenomas: A Case-Cohort Study

H. C. Jodal, P. Wieszczy-Szczepanik, D. Klotz, M. Herfindal, I. Barua, P. Tag, L. M. Helsing, E. Refsum, Ø. Holme, H.-O. Adami, M. Bretthauer, M. Kalager, and M. Løberg

See editorial on page 333.

Newer adenoma risk classification systems may reduce the burden of colonoscopy surveillance at the cost of a small increase in colorectal cancer incidence among low-risk individuals.

RESEARCH LETTERS

492 Low-Dose Interleukin 2 for the Treatment of Moderate to Severe Ulcerative Colitis

J. R. Allegretti, V. Mitsialis, J. B. Canavan, Low-Dose IL2 UC Study Group, and S. B. Snapper

496 Odevixibat Treatment Induces Biliary Bile Acid Secretion in Responsive Patients With Bile Salt Export Pump Deficiency

M. Nomden, F. Kuipers, J. B. F. Hulscher, E. Lindström, V. Valcheva, and H. J. Verkade

499 Effects of FGF19 Analogue Aldafermin in Patients With Bile Acid Diarrhea: A Randomized, Placebo-Control Trial

J. BouSaba, M. Torres, S. Dilmaghani, W. S. Harmsen, L. Ling, and M. Camilleri

502 Intratumoral *Malassezia globosa* Levels Predict Survival and Therapeutic Response to Adjuvant Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma

K. Okuno, M. Tokunaga, D. Von Hoff, Y. Kinugasa, A. Goel, and The PDAC Biomarker Working Group

505 Discovery and Initial Characterization of Long Intergenic Noncoding RNAs Associated With Esophageal Adenocarcinoma

D. Ravillah, A. L. Kieber-Emmons, S. Singh, BETRNet Consortium, K. Keerthy, A. E. Blum, and K. Guda

509 ChatGPT Answers Common Patient Questions About Colonoscopy

T.-C. Lee, K. Staller, V. Botoman, M. P. Pathipati, S. Varma, and B. Kuo

See editorial on page 336.

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

e21 CME Exam 1: Effect of *Helicobacter pylori* Eradication Therapy on the Incidence of Noncardia Gastric Adenocarcinoma in a Large Diverse Population in the United States

GASTRO DIGEST

- 512 Colorectal Neoplasia 10 Years or More Following Negative Colonoscopy: Time to Extend Recommended Surveillance Intervals?**

N. Forbes

- 512 Maternal Diet and Risk of Obesity in Offspring**

S. Ghoneim

- 513 Next-Generation Farnesoid X Receptor Agonists in NASH Treatment: Are We There Yet?**

B. J. DeBosch

- 514 Genomic Analysis of Hair From Celebrated Composer Provides Insight Into Liver Disease Susceptibility**

S. Naimimohasses and M. Bhat

CORRESPONDENCE

- 515 Microbial Riboflavin Biosynthesis Associates With Response to Dietary Fiber Consumption: Time to Personalize Adjunct Therapy in Patients With Inflammatory Bowel Disease?**

A. R. Bourgonje

- 516 Reply**

H. Armstrong, R. Sigall-Boneh, and E. Wine

- 517 Assessing the Level of Expertise of Endoscopists in Optical Diagnosis of Colorectal Polyps—Not Every Expert Is an Expert**

Q. E. W. van der Zander, F. van der Sommen, and E. J. Schoon

- 518 Regarding “Final Analysis of Diagnostic Endoscopic Resection Followed by Selective Chemoradiotherapy for Stage I Esophageal Cancer: JCOG0508”**

Y. Wada and N. Mori

- 519 Reply**

K. Nihei, K. Minashi, and M. Muto

- 520 Efficacy and Safety of Drugs for Gastroparesis: Dopamine Receptor Antagonists Should Not Be Considered as a Single Pharmacologic Entity**

G. J. Sanger and P. L. R. Andrews

- 521 Substantial Variability in Placebo and Nocebo Responses Challenges the Validity of Network Meta-Analysis of Gastroparesis Pharmacotherapy**

D. Wu, G. Yu, and G.-F. Li

- 522 Reply**

M. R. Ingrosso, C. J. Black, and A. C. Ford